TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05113693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393
Description: QD, PO
Study: NCT05444127

Intervention type: OTHER
Intervention: Questionnaire OHIP-14
Description: A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.

Intervention type: OTHER
Intervention: Questionnaire OHIP-14
Description: A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
Study: NCT05113693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, H053
Description: QD, PO
Study: NCT06388057

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative Small Bowel Ultrasonography
Description: An intraoperative ultrasound study will be performed on the intestinal segment identified as the resection site
Study: NCT05113693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, H053
Description: QD, PO
Study: NCT05444127

Intervention type: OTHER
Intervention: Thorough dental examination
Description: A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.

Intervention type: OTHER
Intervention: Thorough dental examination
Description: A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
Study: NCT06042335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAISe EZ
Description: DAISe Thrombectomy System for mechanical thrombectomy
Study: NCT05273151

Intervention type: DEVICE
Group type: OTHER
Intervention: KOS (Intranasal kinetic oscillation stimulation)
Description: Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
Study: NCT04561180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-009A
Description: Administered as an Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-009A
Description: Administered as an Intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EG-009A Placebo
Description: Administered as an Intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: The comparator, Administered as an Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The comparator, Administered as an Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The comparator, Administered as an Intravenous infusion
Study: NCT06656195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glueus maximus strengthening
Description: In week 1 SIJ Mobilization along with ,Single leg bridge ,alternating leg lifts ,clam Exercise,Prone hip extension with knee flexion. In week 2 SIJ Mobilization along with Side-squats,Star excursion exercise,Forward step-down.In week 3 SIJ Mobilization along with bilateral squat ,single leg squat ,split squat/lunge ,frontal step up ,lateral step up.In week 4 SIJ mobilization along with bilateral squat with a band and hip extension against resistance was done.Three times a week for 4 weeks In each session, a total of two sets of 12 repetitions each were carried out, with a 1 min rest time between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hamstring stretching group
Description: SIJ mobilization and Soft tissue mobilization along with Static Hamstrings stretching (3 sets, 15 repetitions with a holding time of 15 seconds ,3 times a week for 4 week) and Dynamic hamstrings stretching(3 set, 15 repetitions with a holding time of 1 second, 3 times a week for 4 weeks.
Study: NCT04613206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose Quadrivalent Inactivated Influenza Vaccine
Description: Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
Study: NCT04985565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participate in Mediterranean diet
Study: NCT04533269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arnica montana, Ledum palustre
Description: Homeopathic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arnica montana, Ledum palustre
Description: Homeopathic
Study: NCT04985565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo standard of care radical prostatectomy
Study: NCT06250309

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary assignment
Description: A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary assignment
Description: A total of 48 subjects will be randomized by a computer program into one of two groups: MD or WD. Participation in each dietary arm lasts 8 weeks, with a 6 week washout period in between each arm.
Study: NCT04826718

Intervention type: OTHER
Intervention: Questionaire
Description: A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls).

Intervention type: OTHER
Intervention: Questionaire
Description: A questionnaire will be administered to all participants to evaluate exposures related to infection at the baseline (enrollement) - Baseline questionnaire. A Follow-up questionnaire to all participants will be done after 3 and 6 months.~Capillary blood collection, for diagnosis of anti-SARS-CoV-2 Antibodies by rapid test, will be done at the first interview, for all participants (cases and controls).~Collection of peripheral venous blood, for analysis of the presence and duration of anti-SARS-CoV-2 Antibodies (N and S) will be done at the first interview, and after 6 months for all participants (cases and controls).
Study: NCT06406608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Description: This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
Study: NCT04166734

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
Study: NCT05253950

Intervention type: OTHER
Intervention: Questionnaire
Description: answered questions from two standard questionnaires the Internet Addiction Test (IAT) which examines students' dependence on the internet and the Nordic Muscuskeletal Questionnaire (NQS) which examines the onset of symptoms from the musculoskeletal system
Study: NCT04391621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Derived stem cell transplantation
Description: Through liposuction, harvested lipoaspirate will be processed in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for inflitration. This will then be infiltrated into the affected keloid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
Description: Triamcinolone Acetanoide 40mg/ml suspension will be diluted into 1ml of 0.5% lignocaine solution and infiltrated into the selected keloid.
Study: NCT05546138

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsies with quantification of intra-epidermal nerve fibre density
Description: Skin biopsy

Intervention type: DIAGNOSTIC_TEST
Intervention: Perception Threshold Tracking
Description: Transcutaneous stimulation of large and small nerve fibres using weak electrical currents

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermal perception thresholds
Description: Heat and cold perception thresholds

Intervention type: DIAGNOSTIC_TEST
Intervention: Corneal confocal Microscopy
Description: Corneal nerve fibre density, corneal nerve fibre length, corneal nerve branch density

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Functional and structural MRI pictures of peripheral nerves and CNS

Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies
Description: Nerve conduction and amplitude of Sural nerve

Intervention type: OTHER
Intervention: Composite scores and questionnaires
Description: Composite scores and questionnaires
Study: NCT05357729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiSense® remote monitoring
Description: At hospital, the patient will be monitored with conventional monitoring devices as well as the MultiSense® solution (at least one hour with a reference monitor). After hospital discharge, the patients will be remotely monitored by their healthcare professional using the MultiSense® solution.
Study: NCT05275998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-365/TMB-380
Description: Monoclonal antibodies to be given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-365/TMB-380
Description: Monoclonal antibodies to be given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-365/TMB-380
Description: Monoclonal antibodies to be given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-365/TMB-380
Description: Monoclonal antibodies to be given intravenously
Study: NCT04916548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
Study: NCT05743582

Intervention type: PROCEDURE
Intervention: Bronchoscopy for sample collection
Description: Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.

Intervention type: PROCEDURE
Intervention: Bronchoscopy for sample collection
Description: Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
Study: NCT04724941

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05941065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balancing gel cream
Description: Skin balancing gel cream will be applied onto clean skin morning and night
Study: NCT06097819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app-based game group
Description: Mobile app based game therapy+Occupational therapy+Sensor-based game therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised combined sensor-based game group
Description: Occupational therapy+Sensor-based game therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized occupational therapy group
Description: Occupational therapy
Study: NCT05900635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Glycine Sulfate
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Glycine Sulfate
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
Study: NCT05743582

Intervention type: PROCEDURE
Intervention: Bronchoscopy for sample collection
Description: Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.

Intervention type: PROCEDURE
Intervention: Blood donation
Description: Participants will donate a single blood sample for isolation of immune cells from peripheral blood.

Intervention type: PROCEDURE
Intervention: Blood donation
Description: Participants will donate a single blood sample for isolation of immune cells from peripheral blood.

Intervention type: PROCEDURE
Intervention: Blood donation
Description: Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
Study: NCT05574049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrocannabivarin
Description: The subjects will take once daily oromucosal strip with intervention drug for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetrahydrocannabivarin
Description: The subjects will take once daily oromucosal strip with intervention drug for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrocannabivarin
Description: The subjects will take once daily oromucosal strip with intervention drug for 90 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The subjects will take once daily oromucosal strip with no drug on it for 90 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The subjects will take once daily oromucosal strip with no drug on it for 90 days
Study: NCT04289038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic Relaxation
Description: Autogenic relaxation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality game application
Description: virtual reality game application,

Intervention type: OTHER
Group type: OTHER
Intervention: kidney function narration
Description: kidney function narration
Study: NCT06100601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANS regulation therapy
Description: innovative intervention for functional dysphonia
Study: NCT04742179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manteinance and care intervention on the green areas.
Description: Manteinance and care intervention on the green areas.
Study: NCT04595279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking sessions
Description: Participants undergo topography and behavioral economic sessions where they can make choices to earn cigarette puffs by pulling plungers on experimental equipment
Study: NCT02897414

Intervention type: OTHER
Intervention: Surveillance of state medical examiner databases
Study: NCT06100601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional voice therapy (CVT)
Description: conventional voice therapy traditionally provided for functional dysphonia

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ANS regulation therapy + CVT
Description: combination of ANS regulation therapy and CVT
Study: NCT02897414

Intervention type: OTHER
Intervention: Surveillance of state medical examiner databases

Intervention type: OTHER
Intervention: Surveillance of state medical examiner databases

Intervention type: OTHER
Intervention: Surveillance of state medical examiner databases

Intervention type: OTHER
Intervention: Surveillance of state medical examiner databases
Study: NCT05631587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WExercise
Description: A 10-weekly technology-based intervention delivered in a mobile application using the M-PAC framework to promote PA in post-treatment cancer survivors. Participants will be given individualised access to the app. Participants will be sent reminders (3 days apart) by WhatsApp/WeChat each time they have a class due.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A control group receiving an information sheet for self-directed exercise.
Study: NCT05205876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eddii mobile application
Description: Participants will use the Eddii mobile application in the intervention arm.
Study: NCT06447051

Intervention type: OTHER
Intervention: Kasai Surgery
Description: As per institute treatment protocol
Study: NCT04606719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Platelet Rich fibrin
Description: Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Advanced Platelet Rich fibrin
Description: Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Platelet Rich fibrin
Description: Preparing of A-PRF by drawing 5 mL of venous blood from the patient in dried glass test tube and immediately centrifuging it at 1500 rpm for 14 minutes